… There were 48,296 non-small cell lung cancer (NSCLC) patients analyzed between 2009 …
In this study, data from 37,463 lung cancer patients were analyzed. 28,980 patients (77.4%) …

… Several patients in our study had sustained disease control. PD-L1 expression on tumor
cells or tumor-infiltrating immune cells did not differ in this subgroup. Next-generation …

… Lung cancer is the leading cause of cancer-related death worldwide with a high … cell lung
cancer (NSCLC) is the most common type of lung cancers, representing ~90% of all cases (2). …

… Various tumour-based and/or blood-based assays have been evaluated for their ability to
predict clinical benefit from immune-checkpoint inhibitors in patients with small-cell lung cancer…

… SCLC makes up about 15% of lung cancer cases. Patients with SCLC typically present
with respiratory symptoms, including cough, dyspnoea (laboured breathing) or haemoptysis (…

… A phase I study to evaluate the safety and clinical activity of durvalumab in … -cell lung cancer
was performed in 2017. In this study, 30 patients in the expansion phase received treatment, …

… This requires a better understanding of the T cells in the lungs of patients with NSCLC.
Here, we report T cell repertoire analysis in a cohort of 236 early-stage NSCLC patients. T …

… patients. Here we report an extensive molecular and immune … study of 245 Chinese patients
with non-small cell lung cancer. Tumor-infiltrating lymphocyte estimated using immune cell …

… with early-stage lung cancer has rapidly expanded. In this Review, we … the treatment of
patients with early-stage lung cancer and explore the current and future state of clinical research …

… Small-cell lung cancer (SCLC) is an aggressive disease with distinct pathological, clinical,
and molecular characteristics from non–small-cell lung cancer. SCLC has high metastatic …